<DOC>
	<DOCNO>NCT02318537</DOCNO>
	<brief_summary>This Phase 3 trial enroll participant diagnose Lennox-Gastaut Syndrome ( LGS ) still experience least 4 motor seizure involve trunk extremity per week , despite ongoing treatment 3 antiepileptic drug ( AEDs ) meet inclusion/exclusion criterion . Following 28-day baseline period , participant begin 84-day treatment period . Participants assign receive twice daily dos placebo cannabidiol oral solution high dose determine safe previous trial . Following study completion , participant invite receive Cannabidiol Oral Solution open label extension study ( separate protocol ) .</brief_summary>
	<brief_title>Cannabidiol Oral Solution Adjunctive Therapy Treatment Participants With Inadequately Controlled Lennox-Gastaut Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criterion qualification contraception , include clinical diagnosis refractory LGS onset seizure accord protocolspecified criterion Is able speak understand language study conduct , able understand procedure study requirement voluntarily sign date informed consent form approve Institutional Review Board conduct study procedure In opinion Investigator , participant parent ( ) /caregiver ( ) willing able comply study procedure visit schedule , include venipuncture , twice daily dose , accurate diary , Followup Visits ( applicable ) . Medical history outside protocolspecified parameter Clinically significant history allergic reaction significant sensitivity cannabinoids ingredient study drug Inadequate supervision parent guardians History current use dietary supplement , drug overthe counter medication outside protocolspecified parameter Signs , symptoms history condition , per protocol opinion investigator , might compromise : 1 ) safety wellbeing participant study staff ; 2 ) safety wellbeing participant 's offspring ( pregnancy breastfeed ) ; 3 ) analysis result</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment-resistant seizure</keyword>
</DOC>